几丁质酶3样1酶联试剂盒 YKL-40

几丁质酶3样1是
反映恶性肿瘤、糖尿病、心肌梗死、 哮喘、肺部感染、炎症、精神分裂症的一个生物标示物

Létuvé S, et al. YKL-40 is elevated in patients with chronic
obstructive pulmonary disease and activates alveolar macrophages. 
J Immunol. 2008 Oct 1;181(7):5167-73. 

Rathcke CN, et al. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 
diabetes and increases with levels of albuminuria. Diabetes Care. 2009
Feb;32(2):323-8. Epub 2008 Oct 28.

1. Serum levels of YKL-40 increases in patients with acute myocardial infarction.
   

   Nøjgaard C, et al. Coron Artery Dis. 2008 Jun;19(4):257-63.
   

   OBJECTIVES: YKL-40 is secreted by macrophages, including those in atherosclerotic
   plaques, neutrophils, and vascular smooth muscle cells. Circulating YKL-40 is
   elevated in patients with inflammation and increased tissue remodeling. The aim
   was to examine the sequential changes in serum YKL-40 in patients with acute
   myocardial infarction (AMI), with and without thrombolytic therapy, as compared
   with patients with stable coronary artery disease (CAD). METHODS: YKL-40 was
   measured by radioimmunoassay in serum from 63 patients. A total of 47 patients
   had their first AMI [30 with ST segment elevation myocardial infarction (STEMI)
   were thrombolyzed, 17 with non-STEMI were not thrombolyzed] and 16 patients had
   CAD. RESULTS: Serum YKL-40 at the time of admission was higher in patients with
   AMI (median: 156 microg/l, range: 40-3000 microg/l) than in patients with CAD
   (median: 106 microg/l, range: 54-300 microg/l, P=0.048) and healthy participants 
   (median: 102 microg/l, range: 38-514 microg/l, P<0.001). No difference in serum
   YKL-40 between CAD patients and healthy participants (P=0.89) was observed. No
   difference in serum YKL-40 between the AMI patients with or without ST-elevations
   (P=0.12) was observed. The maximum serum YKL-40 during the first 24 h after
   admission was higher in thrombolyzed STEMI patients than in the nonthrombolyzed, 
   non-STEMI patients (P=0.01) and the CAD patients (P<0.0001). Serum YKL-40
   declined consistently from the maximum value just after the AMI and during
   follow-up. Serum YKL-40 at 90, 180, and 360 days after AMI were significantly
   higher in nonthrombolyzed than in thrombolyzed patients (P=0.004, P=0.008,
   P=0.017, respectively). CONCLUSION: These results demonstrated that serum
   concentrations of YKL-40 are greatly increased in AMI patients with and without
   thrombolytic therapy.

2. Furuhashi K, et al. Increased expression of YKL-40, a

   chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010 Mar 26. [Epub ahead of print] 

3. Comabella M, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 Apr;133(Pt 4):1082-93. Epub 2010 Mar 17.

4. Chupp GL, et al. A chitinase-like protein in the lung and circulation of patients with severe  asthma. N Engl J Med. 2007 Nov 15;357(20):2016-27.

5. Ober C, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008 Apr 17;358(16):1682-91. Epub 2008 Apr.